Simulation of various randomization strategies for a clinical trial in sickle cell disease

William J. Meurer¹, Jason T. Connor²-³, Jeffrey Glassberg⁴

¹Departments of Emergency Medicine and Neurology, University of Michigan, Ann Arbor, MI, USA, ²Berry Consultants, Austin, TX, USA, ³University of Central Florida College of Medicine, Orlando, FL, USA, ⁴Departments of Emergency Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Objective: To use numerical simulation to evaluate various randomization strategies for a clinical trial in sickle cell disease (SCD).

Methods: The Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events trial* is a randomized, controlled, feasibility study of inhaled mometasone for individuals with SCD who do not have asthma. The target sample size is 45 patients and one goal is to limit imbalance with respect to two important covariates (1) hydroxyurea use and (2) historical emergency department (ED) utilization. We compared three methods of patient allocation (simple randomization, block randomization, and biased-coin adaptive randomization) using numerical simulation (10 000 trials). The primary outcome measure was the proportion of simulated trials with numerically apparent differences in the two covariates: hydroxyurea use (binary) and ED utilization (three-level ordinal).

Results: Overall, only 1.6% of simulated trials had any covariate comparison with $P < 0.3$ across groups for simple randomization, and 0% for both the block and adaptive randomization. In trials where the total sample size was 45 patients, the block randomization strategy achieved the greatest balance because participants were deterministically assigned to the treatment arm that balanced covariates. The adaptive strategy achieved similar results without deterministic treatment assignments even when trials included only 45 patients.

Discussion: Adaptive clinical trial designs have potential to mitigate some of the challenges that have hampered SCD trials. In small exploratory trials, even non-statistically significant differences in important covariates can threaten interpretability and external validity.

Conclusion: Adaptive randomization performed similarly to block randomization and offers advantages including better allocation concealment and less ability for investigators to predict the next assignment.

Keywords: Sickle cell disease, Clinical trials, Bayesian statistics, Adaptive clinical trials

Introduction

Sickle cell disease (SCD) is an inherited disorder of hemoglobin that affects approximately 100 000 Americans.¹ In individuals who suffer from the disease, a complex state of hemolysis, inflammation, vascular damage, and cell adhesion manifests disease-related pathology in all organs but the most common manifestation is the vaso-occlusive painful episode. Healthcare expenditures for acute care utilization in SCD have reached $1.5 billion per year.²³

Despite the staggering costs of SCD, hydroxyurea remains the only FDA-approved medication to treat the disease. While the molecular pathophysiology of SCD is well understood, efforts to develop new therapies have been fraught with failure.⁴ In SCD, where disease prevalence can hamper recruitment, trial design inefficiencies become a critical barrier to progress.⁵⁻⁸

Adaptive clinical trial designs have potential to mitigate some of the challenges that have hampered SCD trials in the past and one aspect of adaptive trial design that has potential to increase efficiency of small, early-phase trials is adaptive covariate-balanced randomization. Small clinical trials are challenging as a general rule, and particularly challenging is SCD. As such, even small, non-statistically significant differences in important covariates can potentially threaten the interpretability and external validity of small
sample size exploratory trials. While randomization should generally balance covariates, the risk of a numerically meaningful imbalance increases with a small sample size. For example, within a trial of 40 patients, if one treatment arm has 60% patients with hydroxyurea use and the other has 20%, this difference is important to those interpreting the results, but may not be statistically significant. The risk of such imbalances is best quantified using numerical simulation. As such, the planners of the trial can compare various methods of patient allocation (simple randomization, block randomization, or adaptive randomization) using simulations over several important situations. In the current investigation, our aim was to compare the risk of significant covariate imbalance using three potential randomization strategies within a 45-patient SCD trial.

**Methods**

**Clinical problem**

The detailed methods and rationale for the Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events (IMPROVE) trial have been previously described elsewhere (https://clinicaltrials.gov/ct2/show/NCT02061202). Briefly, the IMPROVE trial is a randomized, controlled, feasibility study of inhaled mometasone for individuals with SCD who do not have asthma (1K23 HL119351 01). The trial was conceived in response to data that, in individuals with SCD, is associated with increased rates of pain and death.

**Trial design and needs**

The proposed trial is a pilot randomized controlled trial of inhaled corticosteroids for patients with SCD. This is a double-blinded, placebo-controlled trial with a primary objective of establishing feasibility and collecting preliminary measurements on important biomarkers. The intended maximum N for this trial is 45, with 2:1 allocation between active treatment and placebo. Two important prognostic baseline covariates are intended to be balanced using adaptive randomization: hydroxyurea use (prevalence about 60%), and emergency department (ED) utilization (categorical low, medium, and high with 40% each in the low and medium categories and 20% in the high category.) Exact balance on the 2:1 allocation was determined a priori to be of lower importance than maintaining balance on the clinical covariates.

**Potential approaches to balancing covariates**

The simplest approach would be individual-level randomization with a biased coin (33.3% probability of placebo) while ignoring covariates. A more typical approach would be block randomization (where patients are randomized in groups of three, with each group having one of its members selected at random to receive placebo). This approach raises concerns about allocation concealment and does not address covariate balance. A more sophisticated approach would use stratified, block randomization, where each of the six possible combinations of covariates would be issued blocks of size 3, with the member receiving placebo randomly determined within each. This approach also has the potential for the investigators to predict, or know the next subject allocation. (For example, if the first subject in the block is assigned placebo, the next two will receive active treatment.) Finally, an innovative approach is to use adaptive randomization, where the probability of receiving active treatment or placebo is never deterministic, and the bias of the coin is adjusted with the goal of maintaining balance on the covariates, along with relative closeness to the 33.3% placebo ratio. For the IMPROVE trial, an additional important goal was demonstrating the feasibility of using a real-time, continuously updating program to provide treatment assignments to the study team.

**Description of adaptive approach**

There are two key variables that we aim to balance: use of hydroxyurea and frequency of ED visits. Hydroxyurea is dichotomized by whether the patient is currently taking the medicine. ED use is split into three groups; subjects with <5 ED, 5–10, or 11–15 ED visits in the previous 12 months. Therefore, there are six subsets of covariate combinations, and we aim to produce an algorithm that measures the imbalance between placebo and treatment within each subgroup.

The procedure works as follows. The first two trial patients are randomized with 1/3 probability to placebo and 2/3 to the treatment without any adjustment for covariates. For patients 3–45, when a patient is randomized, it is first determined which subset the patient belongs to. Then, the algorithm calculates the imbalance to be larger or smaller if the next patient is assigned to treatment or placebo. For each subject assigned to placebo, the imbalance matrix for that type has 1 added to it; for each subject assigned to treatment, the imbalance matrix has 0.5 subtracted from it. Therefore, within each covariate type, balance will be achieved by assigning one subject to placebo and two to treatment. When calculating imbalances across groups at the end of the simulated trials, the actual proportions were used. The three levels of ED utilization were described with binary indicator variables for high and moderate utilization, and hydroxyurea use. For example, if 45% of placebo patients received hydroxyurea, and 60% of treatment patients received hydroxyurea that would be summarized by an imbalance of −15%, the difference in proportions
randomization vector will remain at 1 and tic assignments.) If already at balance (1 for placebo of either zero or one (as we wish to avoid deterministic imbalance if the next patient is assigned to placebo and the proposed imbalance if the next patient is assigned to treatment. The term e represents Euler’s constant. The use of the exponential in this case allows zero imbalance situations to remain at the baseline randomization probability of 1/3. In addition, the exponential function produces a positive value below 1 for negative imbalances, and a positive value greater than 1 for positive imbalances and therefore adjusts the randomization probability appropriately, while never reaching a randomization probability for treatment of either zero or one (as we wish to avoid deterministic assignments.) If already at balance (1 for placebo and −1 for treatment), the sum will be zero and the randomization vector will remain at 1/3. If the sum imbalance is negative (too many patients within this covariate type on treatment), the equation will bias the vector toward assigning the next patient to placebo; if sum imbalance is positive, the vector will bias toward assigning the next patient to treatment.

As an example, if one patient has previously been randomized to treatment in group six (on hydroxyurea, high ED utilization), the imbalance matrix will be at −0.5 for that group. The proposed imbalance if the next patient is randomized to placebo will be 0.5 (adding one), and it will be −1 (subtracting 0.5) if the next patient is randomized to treatment.

\[ \text{imbalance} = v = p^\frac{\text{imbalance}_{\text{placebo}} - \text{imbalance}_{\text{treatment}}}{0.5} \]

In this equation, \( p = 1/3 \) (the desired placebo proportion), and the sum of the proposed imbalance if the next patient is assigned to placebo and the proposed imbalance if the next patient is assigned to treatment. The term e represents Euler’s constant. The use of the exponential in this case allows zero imbalance situations to remain at the baseline randomization probability of 1/3. In addition, the exponential function produces a positive value below 1 for negative imbalances, and a positive value greater than 1 for positive imbalances and therefore adjusts the randomization probability appropriately, while never reaching a randomization probability for treatment of either zero or one (as we wish to avoid deterministic assignments.) If already at balance (1 for placebo and −1 for treatment), the sum will be zero and the randomization vector will remain at 1/3. If the sum imbalance is negative (too many patients within this covariate type on treatment), the equation will bias the vector toward assigning the next patient to placebo; if sum imbalance is positive, the vector will bias toward assigning the next patient to treatment.

As an example, if one patient has previously been randomized to treatment in group six (on hydroxyurea, high ED utilization), the imbalance matrix will be at −0.5 for that group. The proposed imbalance if the next patient is randomized to placebo will be 0.5 (adding one), and it will be −1 (subtracting 0.5) if the next patient is randomized to treatment.

\[ 0.51 = 0.33333^\frac{(0)^{\text{placebo}} + (1)^{\text{treatment}}}{0.5 \text{ placebo} + 0.5 \text{ treatment}} \]

After the proposed vector is calculated, the algorithm determines whether the overall trial placebo proportion is deviating outside the desired range from 0.23 to 0.43. This is to ensure that the trial does not deviate too far from 1:2 randomization. If this condition is met, the algorithm overrides the previous proposed vector using the following equation:

\[ \text{imbalance} = v = p^\frac{\text{imbalance}_{\text{current}}}{p} \]

Again, \( p \) represents the desired placebo proportion of 1/3 and \( p_{\text{current}} \) is the overall proportion of patients assigned to placebo within the trial so far. It is important to note that this will still not result in deterministic assignments, and will either decrease or increase the probability of placebo assignments to bring the overall trial placebo proportion into the 0.23–0.43 range. When enforcing this range, the algorithm will ignore covariate imbalance. As an example, if the current proportion of placebo is 0.5 (above the upper threshold of 0.43), then the randomization vector is calculated as follows:

\[ \text{imbalance} = v = 0.33333^{0.5/0.3333} = 0.1924 \]

An extreme yet unlikely example is the case of all subjects receiving placebo. The probability of placebo assignment in this case would be 0.037.

**Comparisons**

We compared this using simulation to simple randomization (using a binomial distribution with 0.333 placebo probability) and block randomization (using three patient blocks for each of the six combinations) and simulated 10 000 trials using the R statistical package software. We first present the results of a single example simulated trial to further illustrate the algorithm procedure, and summarize the differences between the treatment and placebo groups.

Imbalances were calculated at the end of each trial and summarized as a difference in proportions, subtracting the treatment group from the placebo group. The overall imbalance was calculated as the sum of imbalance on hydroxyurea plus the sum of the average imbalance on moderate ED utilization and high ED utilization (this calculation was conducted such that imbalance on one covariate in favor of placebo would tend to be counteracted by imbalance on another covariate in favor of treatment). We also calculated Absolute Sum Imbalance, where the absolute value of the imbalances arrived at by subtracting the treatment group proportions from the placebo group proportions was used.

**Sensitivity analysis**

We expected that with the increasing sample size, the adaptive randomization approach would be exceedingly similar to the block randomization. We repeated the simulations using a total trial sample size of 450, again with 2:1 allocation of treatment to placebo.

**Results**

The progress and treatment allocation decisions of the single example trial are presented in Table 1. Note the randomization vector calculated for patient 45 of 0.51 and is the same as the example provided in the methods of the imbalance matrix starting at −0.5 for that subset. In this example trial, the rule for having too high a proportion of placebo patients triggered for patients 3 through 7. Good numerical balance
Table 1 Example trial and status of imbalance and proposed randomization vectors with treatment assignments

| Patient number | Hydroxyurea utilization | Placebo proportion prior to randomization | Hydroxyurea imbalance | Moderate ED imbalance | High ED imbalance | Overall weighted imbalance | Randomization vector (probability of placebo) | Assignment |
|----------------|--------------------------|------------------------------------------|-----------------------|----------------------|-------------------|--------------------------|---------------------------------------------|------------|
| 1              | Taking Moderate          | 0*                                       | 0                     | 0                    | 0                 | 0                        | 0.33*                                       | Treatment |
| 2              | Not taking High          | 0*                                       | 0                     | 0                    | 0                 | 0                        | 0.33*                                       | Placebo  |
| 3              | Taking Low               | 0.50                                     | 0.07                  | 0.07                 | 0.07              | 0.07                     | 0.11                                        | Placebo  |
| 4              | Taking Moderate          | 0.67                                     | 0.50                  | 0.07                 | 0.50              | 0.07                     | 0.19                                        | Treatment |
| 5              | Taking Moderate          | 0.50                                     | 0.33                  | 0.07                 | 0.33              | 0.07                     | 0.19                                        | Placebo  |
| 6              | Taking Moderate          | 0.60                                     | 0.33                  | 0.07                 | 0.33              | 0.07                     | 0.14                                        | Treatment |
| 7              | Not taking Moderate      | 0.50                                     | 0.07                  | 0.07                 | 0.07              | 0.07                     | 0.19                                        | Treatment |
| 8              | Taking High              | 0.38                                     | 0                     | 0.33                 | 0                 | 0.33                     | 0.16                                        | Treatment |
| 9              | Not taking Moderate      | 0.33                                     | 0.10                  | 0.38                 | 0.05              | 0.38                     | 0.51                                        | Treatment |
| 10             | Not taking Moderate      | 0.30                                     | 0.17                  | 0.42                 | 0.08              | 0.42                     | 0.78                                        | Treatment |
| 11             | Not taking Moderate      | 0.27                                     | 0                     | 0.25                 | 0                 | 0.25                     | 0.91                                        | Placebo  |
| 12             | Taking Low               | 0.33                                     | −0.06                 | −0.17               | 0.03              | −0.17                    | 0.19                                        | Treatment |
| 13             | Taking High              | 0.31                                     | 0.04                  | 0.27                 | 0.18              | 0.27                     | 0.51                                        | Placebo  |
| 14             | Not taking Moderate      | 0.36                                     | 0.10                  | 0.30                 | 0.20              | 0.30                     | 0.51                                        | Treatment |
| 15             | Not taking Low           | 0.33                                     | 0.15                  | 0.24                 | 0.22              | 0.24                     | 0.51                                        | Treatment |
| 16             | Taking Moderate          | 0.31                                     | 0.21                  | 0.14                 | 0.15              | 0.14                     | 0.51                                        | Placebo  |
| 17             | Not taking Low           | 0.35                                     | 0.12                  | −0.21                | 0.10              | −0.21                    | 0.51                                        | Placebo  |
| 18             | Taking Moderate          | 0.39                                     | 0.07                  | −0.24                | 0.12              | −0.24                    | 0.01                                        | Treatment |
| 19             | Taking Moderate          | 0.37                                     | 0.03                  | −0.26                | 0.13              | −0.26                    | 0.33                                        | Treatment |
| 20             | Taking High              | 0.35                                     | 0                     | −0.21                | 0.07              | −0.21                    | 0.33                                        | Treatment |
| 21             | Taking Low               | 0.33                                     | −0.03                 | −0.17                | 0.09              | −0.17                    | 0.33                                        | Treatment |
| 22             | Taking Low               | 0.32                                     | −0.05                 | −0.13                | 0.10              | −0.13                    | 0.33                                        | Treatment |
| 23             | Not taking Low           | 0.30                                     | −0.02                 | −0.10                | 0.11              | −0.10                    | 0.33                                        | Treatment |
| 24             | Taking Moderate          | 0.29                                     | 0.04                  | −0.03                | 0.07              | −0.03                    | 0.33                                        | Treatment |
| 25             | Taking Moderate          | 0.32                                     | 0.01                  | −0.06                | 0.08              | −0.06                    | 0.33                                        | Placebo  |
| 26             | Taking Moderate          | 0.31                                     | 0.06                  | 0                    | 0.06              | 0                        | 0.33                                        | Placebo  |
| 27             | Taking Moderate          | 0.33                                     | 0.04                  | −0.02                | 0.06              | −0.02                    | 0.33                                        | Placebo  |
| 28             | Taking Moderate          | 0.32                                     | −0.03                 | 0.02                 | 0.04              | 0                        | 0.33                                        | Placebo  |
| 29             | Not taking Moderate      | 0.34                                     | 0                     | 0.05                 | 0                 | 0                        | 0.33                                        | Placebo  |
| 30             | Not taking High          | 0.34                                     | −0.05                 | 0.07                 | 0.07              | 0                        | 0.33                                        | Placebo  |
| 31             | Not taking Low           | 0.34                                     | −0.07                 | 0.02                 | 0.02              | 0                        | 0.33                                        | Placebo  |
| 32             | Taking Low               | 0.35                                     | −0.04                 | −0.02                | 0.06              | −0.02                    | 0.78                                        | Placebo  |
| 33             | Taking Low               | 0.34                                     | −0.05                 | −0.05                | 0.07              | −0.05                    | 0.78                                        | Placebo  |
| 34             | Taking Moderate          | 0.36                                     | −0.07                 | −0.02                | 0.08              | −0.02                    | 0.78                                        | Placebo  |
| 35             | Taking Low               | 0.35                                     | 0                     | −0.07                | 0.04              | −0.07                    | 0.78                                        | Placebo  |
| 36             | Not taking High          | 0.34                                     | −0.04                 | 0                    | 0.04              | 0                        | 0.78                                        | Placebo  |
| 37             | Not taking Moderate      | 0.33                                     | −0.09                 | 0.04                 | 0.02              | 0                        | 0.78                                        | Placebo  |
| 38             | Not taking Moderate      | 0.35                                     | −0.06                 | 0.02                 | 0.03              | 0.02                     | 0.78                                        | Placebo  |
| 39             | Taking Moderate          | 0.34                                     | −0.08                 | 0                    | 0.04              | 0                        | 0.78                                        | Placebo  |
| 40             | Taking Low               | 0.33                                     | −0.09                 | 0.02                 | 0.05              | 0.02                     | 0.78                                        | Placebo  |
| 41             | Taking High              | 0.33                                     | −0.10                 | 0.04                 | 0.02              | 0.02                     | 0.78                                        | Placebo  |
| 42             | Taking Low               | 0.32                                     | −0.12                 | 0.06                 | 0.02              | 0.02                     | 0.78                                        | Placebo  |
| 43             | Taking Low               | 0.31                                     | −0.08                 | 0.02                 | 0.01              | 0.02                     | 0.78                                        | Placebo  |
| 44             | Taking Low               | 0.33                                     | −0.06                 | −0.02                | −0.01             | −0.02                    | 0.51                                        | Placebo  |
| 45             | Taking High              | 0.34                                     | −0.07                 | 0                    | −0.03             | 0                        | 0.51                                        | Treatment |

The progress and treatment allocation decisions of the single example trial. Weighted overall imbalance is the sum of the hydroxyurea imbalance and one-half times the sum of the moderate and high ED imbalances.

*The first two patients are enrolled with a 1/3 probability of placebo.
was achieved between the groups for all levels of the covariates and no statistically significant differences were observed (Table 2).

Overall, only 1.6% of simulated trials had any covariate comparison with $P < 0.3$ on Fisher’s exact test across groups for simple randomization, and 0% for both the block and adaptive randomization. Figure 1 shows trial performance across the three methods. Tables 3 and 4 summarize the magnitude of imbalances and the probability of observing imbalances measured using the two methods (sum or sum of absolute values). In trials where the total sample size was 45 patients, as expected, the block randomization strategy achieved the greatest balance because participants were deterministically assigned to the treatment arm that balanced covariates. The adaptive strategy was able to achieve similar results without deterministic treatment assignments even when trials included only 45 patients.

Results of sensitivity analysis
We expected that with the increasing sample size, the adaptive randomization approach would be exceedingly similar to the block randomization. We repeated the simulations using trial sample sizes of 100, 200, 300, and 450, again with 2:1 allocation of treatment to placebo. At a sample size of 450, there was nearly complete balance on all covariates and the adaptive randomization algorithm appeared nearly identical on the histograms and quantiles (see supplement).

![Figure 1](https://example.com/figure1.png)

**Figure 1** Performance of the three methods. Histograms depict the final imbalance states of simulated trials of 45 participants. A total of 10,000 sets of virtual patients were generated, and each of the three trial algorithms were applied to each set. For the top four rows, the positive portion of the histogram represents trials with imbalances (and their magnitude) with a higher proportion of that covariate for the placebo group. The bottom row depicts the distribution of final placebo proportion from the various methods.

### Table 2 Baseline characteristics of sample trial

|                | Treatment ($n = 30$) | Placebo ($n = 15$) | $P$-values |
|----------------|----------------------|--------------------|------------|
|                | $n$ | Proportion | $n$ | Proportion | Fisher’s | Chi square |
| Hydroxyurea    | 20  | 0.67       | 9   | 0.60       | 0.746    | 0.913      |
| ED utilization |     |            |     |            |          |            |
| Low            | 9   | 0.30       | 5   | 0.33       | 1        | 0.958      |
| Medium         | 14  | 0.47       | 7   | 0.47       |          |            |
| High           | 7   | 0.23       | 3   | 0.20       |          |            |

Meurer et al. Randomization strategies for a sickle cell trial

Hematology 2016 VOL. 21 NO. 4 245
Discussion

A 2011 report by the Institute of Medicine identified innovative trial design strategies including Bayesian adaptive methodologies as a key tool to accelerate research and development in rare diseases. Here, we report, to our knowledge, the first use of adaptive covariate balancing randomization and the first use of simulation to inform study design in a clinical trial for SCD. R code for this algorithm is provided as a supplement to facilitate use of this technique by other SCD investigators.

The simulations presented demonstrated that an adaptive covariate-balanced randomization strategy achieves similar balance to a traditional block randomization with several benefits including improved masking of investigators and avoiding deterministic treatment assignments. Based on these simulations, we chose an adaptive randomization strategy for the IMPROVE trial. One potential critique of adaptive trials is that they add substantial logistical burden that may outweigh any increase in trial efficiency. Our group designed a simple user interface within the software program R coupled with a file-sharing system. Investigators are able to monitor and maintain the randomization algorithm from off-site and research coordinators have randomized 25 participants to date without difficulty. The file-sharing site does not collect any protected health information, and all changes made are logged and older versions of files can be easily recovered and restored if a subject is randomized in error. While simulation was used here to inform the choice of randomization strategy, it can be used for almost any aspect of trial design to concretely describe the probability of success under various design strategies.

The current study has several important limitations. We report the results of a numerical simulation study as opposed to the conduct of a completed trial. Operational and logistical issues impact real clinical trials, and not simulated ones. The performance of adaptive trial designs can be simulated under a variety of operational stressors such as slow recruitment; in the current investigation, our design was focused only on adapting to baseline covariates and as such simulating scenarios of operational stress did not seem to be helpful. We did not introduce correlations between the covariate types, whereas in practice it is plausible that ED utilization and hydroxyurea use have a relationship. In addition, there are several important covariates known to affect SCD outcomes (gender, fetal hemoglobin, age, etc.), which we chose not to balance on. With increasing numbers of covariates, adaptive balancing provides diminishing returns (while the overall imbalance score can be minimized, between-group differences for some covariates become inevitable); thus, investigators are still forced to choose only a few covariates upon which to balance in a small trial.

An adaptive randomization approach to balancing two categorical covariates along with keeping the treatment to placebo ratio close to 2:1 performed nearly as well as block randomization and offers several potential advantages including better allocation concealment and less ability for the investigator to predict the next assignment. For the purposes of this simulation, we had a goal of 2:1 allocation to drug and placebo and chose an acceptable range of 0.23–0.43 before the coin became biased. The allocation scheme and acceptable deviation range can be modified based on the needs of the trial where larger or smaller deviations from the allocation goal are acceptable. Statistically significant imbalances on the covariates are unlikely within a 45 patient trial; however, this method ensures good numerical balance and less likelihood of imbalances that may compromise the external validity and clinical interpretation of the trial. Based upon the results of these simulations, we chose an adaptive randomization algorithm for the IMPROVE trial. Simulation may be used for all aspects of trial design to avoid pitfalls and increase efficiency especially for studies in rare diseases such as SCD.

Disclaimer Statements

Contributors W.M.: no conflicts of interest to report; conception and design of the study; data analyses; drafting of the manuscript; revision of the manuscript for important intellectual content. J.C.: no conflicts of interest to report; conception and design of the study;
data analyses; drafting of the manuscript; revision of the manuscript for important intellectual content. J.G.: no conflicts of interest to report; conception and design of the study; data analyses; drafting of the manuscript; revision of the manuscript for important intellectual content.

Funding This research was funded by the National Heart, Lung, and Blood Institute (K23 HL119351 Inhaled Mometasone to Promote Reduction in Vaso-Occlusive Events, PI – Glassberg).

Conflicts of interest None of the authors report any conflicts of interest.

Ethics approval The IMPROVE Trial was approved by the National Heart, Lung, and Blood Institute as well as the Icahn School of Medicine Institutional Review Board.

References
1 Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med 2010;38:S512–21.
2 Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010;303:1288–94.
3 Lanzkron S, Carroll CP, Haywood C, Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol 2010;85:797–9.
4 Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood 2012;120:3647–56.
5 Quinn CT, Stuart MJ, Kesler K, Ataga KI, Wang WC, Styles L, et al. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol 2011;155:263–7.
6 Peters-Lawrence MH, Bell MC, Hsu LL, Osunkwo I, Seaman P, Blackwood M, et al. Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials 2012;33:291–7.
7 Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am 2010;24:1005–20.
8 Wang W, Brugnara C, Snyder C, Wynn L, Rogers Z, Kalinyak K, et al. The effects of hydroxyxarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol 2011;152:771–6.
9 Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21: 2971–30.
10 Senn S. Testing for baseline balance in clinical trials. Stat Med 1994;13:1715–26.
11 Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1977;33:103–15.
12 Signorini DF, Leung O, Simes RJ, Beller E, Gebski VJ, Callaghan T. Dynamic balanced randomization for clinical trials. Stat Med 1993;12:2343–50.
13 Cohen RT, Madadi A, Blinder MA, DeBaun MR, Strunk RC, Field JJ. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. Am J Hematol 2011;86:756–61.
14 Glassberg J, Spivey JF, Strunk R, Boslaugh S, DeBaun MR. Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. J Pediatr Hematol/Oncol 2006;28:481–5.
15 Glassberg JA, Chow A, Winiwesky J, Hoffman R, DeBaun MR, Richardson LD. Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity. Br J Haematol 2012 Nov;159(4):472–9. doi:10.1111/j.1365-2141.2012.08301.x [Epub 2012 Sep 12].
16 Glassberg JA, Wang J, Cohen R, Richardson LD, DeBaun MR. Risk factors for increased ED utilization in a multinational cohort of children with sickle cell disease. Acad Emergency Med 2012;19:664–72.
17 Boat TF, Field MJ. Rare diseases and orphan products: accelerating research and development. Washington, DC: National Academies Press; 2010.